Impact of Budesonide Irrigations on Patients With Chronic Rhinosinusitis and Impact on Sinus Surgery Rates

Phase 2

Withdrawn

• Conditions: Chronic Sinus Congestion; Chronic Sinus Infection; Chronic Sinusitis; Chronic Sinusitis - Ethmoidal, Posterior
• Interventions: Drug: Budesonide

• Registration Number: NCT03519061
• Lead Sponsor: Kaiser Permanente

Brief Summary

This study is intended to assess the impact of a 90 day course of high volume budesonide irrigations for patients who have failed other medical therapy and assessing the impact of the budesonide irrigations on the need for sinus surgery.

Detailed Description

Patient who meet eligibility requirements will be given the opportunity to use a budesonide saline rinse twice daily for 90 days. At the completion of this therapy, their clinical situation will be reassessed and patients will either proceed to surgery or not. If eligible patients choose not participate, they will be offered surgery up front. The study will be assessing symptom scores using the SNOT-22 validated patient reported symptoms score, CT scans, and other measures. The study hypothesizes that a significant portion of patients that otherwise would have progressed to surgery will no longer need to have surgery based upon improvements in their overall symptoms scores after using budesonise irrigations.

Study Timeline

• Study First Submitted: 2018-04-26
• Study First Submitted QC: 2018-04-26
• Study First Posted: 2018-05-08
• Study Start: 2019-08-13
• Primary Completion: 2019-08-30
• Study Completion: 2019-10-01
• Status Verified: 2021-01
• Last Update Submitted: 2021-01-12
• Last Update Posted: 2021-01-14

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• adult (>18 yo)
• symptoms consistent with sinusitis for at least 12 weeks,
• undergone maximal medical therapy, including: extended course of antibiotics (21 days minimum), use of topical corticosteroids for a minimum of 6 weeks, use of saline rinses at least once a day for a minimum of 3 weeks
• CT showing evidence of chronic sinusitis.

Exclusion Criteria

• pregnant women,
• age below 18,
• presence of nasal polyps or other nasal masses,
• failure to complete medical therapy,
• normal CT scan,
• intolerance to budesonide or saline irrigations via squeeze bottle (high volume, high flow).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment	Budesonide	This is the group of enrollees who receive budesonide

Primary Outcome Measures

Name	Time	Method
SinoNasal Outcome Test (SNOT 22)	12 months	Improvement in SNOT 22 scores, using a total score value. The total score can range from 0 to 110 in its composite score, with higher values indicating worse symptoms. The outcome would measure improvements beyond the Minimal Clinically Important Difference (MCID) score of 8.9 lower (lower indicating improvement of symptoms).

Trial Locations

Locations (1)

Kaiser Permanante Orange County; 🇺🇸 Irvine, California, United States